Latest Intellectual Property News

Syntara Limited has completed a $0.84 million Share Purchase Plan, boosting its total capital raise to $8.84 million to fund multiple clinical trials and patent development through to Q3 2027.

dorsaVi has secured exclusive rights to two key robotics patents from NTU Singapore, filling critical gaps in safety control and data acquisition to expand into collaborative robotics and exoskeleton markets.

Boresight Ltd (ASX: BST) is seeking to raise $8 million through a public offer to expand its cost-effective military drone manufacturing, targeting growth in the US and European markets.

First Graphene accelerates its US expansion by acquiring MITO Material Solutions, gaining functionalised graphene technologies and a direct commercial foothold in the world’s largest defence and aerospace market.

Racura Oncology has secured $31.2 million in funding to advance its lead cancer drug RC220, including a strategic $1 million private placement to a specialist healthcare investor.

Opthea Limited resumes ASX trading as it pivots to develop OPT-302 for lymphangioleiomyomatosis, outlining a disciplined 18-month staged clinical program backed by A$31.2 million in cash.

Biome Australia has inked a binding deal with Specialty Probiotics Australia to shift its Activated Probiotics manufacturing onshore, aiming to boost gross margins above 65% and streamline working capital within 18 months.

Scalare Partners has acquired Fishburners, Australia’s largest startup community, to deepen its founder network and expand integrated support services across the country.

Simble Solutions has launched a strategic collaboration with Macquarie University to accelerate development of its exclusive zinc oxide nanosensor technology, targeting e-skin applications and integration into its IoT platforms.

Legacy Minerals has locked in a farm-in deal with Aurelia Metals for its Cobar Project, allowing Aurelia to earn up to 90% by funding exploration. This partnership leverages Aurelia's established Cobar Basin operations while Legacy focuses on its flagship Mt Carrington project.

A US court has dismissed Identitii's patent infringement claim against JPMorgan Chase, citing patent ineligibility. Identitii plans to appeal, while its core business remains unaffected.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.